Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

6(66.7%)

Phase 1

3(33.3%)

9Total

Phase 2(6)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05686356Phase 2Active Not Recruiting

A Pan-TB Regimen Targeting Host and Microbe

Role: collaborator

NCT03959566Phase 2Completed

PanACEA Sutezolid Dose-finding and Combination Evaluation

Role: collaborator

NCT01785186Phase 2Completed

Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design

Role: collaborator

NCT01225640Phase 2Completed

PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

Role: lead

NCT01252108Phase 2Withdrawn

Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers

Role: lead

NCT00990990Phase 1Completed

Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers

Role: lead

NCT00871949Phase 1Completed

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

Role: lead

NCT01585636Phase 1Completed

Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers

Role: lead

NCT01218217Phase 2Completed

Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB

Role: collaborator

All 9 trials loaded